XML 28 R14.htm IDEA: XBRL DOCUMENT v3.8.0.1
8. Outstanding Warrants
12 Months Ended
Dec. 31, 2017
Text Block [Abstract]  
Outstanding Warrants

During the years ended December 31, 2017 and 2016, the Company granted 227 thousand common stock warrants, for the extension of certain Notes for each period, respectively. The accredited investors received 2-year warrants exercisable at $0.01 per share as part of note agreements.

 

The weighted average fair value calculations for warrants granted are based on the following weighted average assumptions:

 

Description

  For the year ended December 31  
    2017     2016  
Dividend-yield     0 %     0 %
Risk-free interest rate     1.32 %     0.81 %
Expected volatility     68.5 %     71.8 %
Expected life (years)     2       2  
Market value per share on grant date   $ 1.43     $ 2.56  
Exercise price per share   $ 0.01     $ 0.01  
Fair value per share on grant date   $ 1.42     $ 2.55  

 

For the years ended December 31, 2017 and 2016, Note investors exercised 241 thousand and 233 thousand warrant shares at exercise prices of $0.01 per share, respectively.

 

A summary of historical warrant activity for the years ended December 31, 2017 and 2016 follows:

 

     Warrants Outstanding & Exercisable     Weighted - Average Exercise Price     Average Remaining Term in Years  
Outstanding December 31, 2015     368     $ 3.36       4.61  
Granted     227       0.01          
Exercised     (233 )     0.01          
Expired     (18 )     0.01          
Outstanding December 31, 2016     344     $ 3.33       3.88  
Granted     227       0.01          
Exercised     (241 )     0.01          
Expired     -       0.01          
Outstanding December 31, 2017     330     $ 3.47       3.02  

 

25 thousand of the above outstanding warrants are not vested and exercisable as of December 31, 2017. As of December 31, 2017, the Company had $37 thousand of total unrecognized compensation expense related to warrants which the Company will amortize over the 0.94 years of weighted remaining term.